CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.

ABSTRACT:

Background

To date, almost all studies regarding chimeric antigen receptor (CAR)-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) were performed in refractory/relapsed (r/r) or minimal residual disease-positive patients. CAR-T therapy in remission patients has not been reported.

Aim

To observe the treatment outcome of CAR-T cells for remission B-ALL patients with poor prognosis.

Methods and results

CAR-T treatment was applied to two B-ALL patients in remission status who had poor prognostic factors and refused transplantation, and one case was unable to accept standard chemotherapy owing to multiple complications. The procedure of CAR-T therapy in these two remission patients was the same as that in r/r B-ALL patients. Lentiviral vectors encoding second

SUBMITTER: Yin Z 

PROVIDER: S-EPMC9575491 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature